Purchase Order 75N95023P00294
Award Date
5/22/23
Potential Completion Date
8/25/23
Potential Value
$75K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Insphero Inc.
Ultimate Awardee
Insphero AG
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Brunswick, ME 04011, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, has awarded a $96,829.63 firm-fixed-price purchase order to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies. The contract is for a Transcriptomics study - RNA-seq in Liver Spheroids Phase One, with the purpose of evaluating the safety and liver toxicity of candidate antisense oligonucleotides using a 3D liver microtissue...
This firm-fixed-price purchase order contract was awarded by the National Institute on Drug Abuse, a civilian agency within the U.S. Department of Health and Human Services, to Insphero Inc., a foreign-owned, for-profit manufacturer of advanced 3D cell culture technologies. The $46,829.63 contract tasks Insphero with providing 3D liver microtissues composed of human primary hepatocytes and other liver cells, which are used for drug-induced liver injury assays and toxicity testing. These...
This is a $90,414 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies and in vitro models. The contract is for a Liver Assay in Liver Spheroids to evaluate the toxicity of short interfering RNA (siRNA) and antisense oligonucleotides (ASOs), which are increasingly being used as...
Insphero, Inc. has been awarded a firm fixed price purchase order valued at twenty-two thousand eight hundred dollars from the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences. The contract calls for Insphero to provide 3D liver microtissues composed of human primary hepatocytes and liver cells for drug testing and safety assessments. Insphero will deliver the 3D liver spheroids to support drug-induced liver injury assays...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $150,000.00 firm fixed-price purchase order to 3Dnamics Inc., a biotechnology company, for services related to the differentiation and characterization of induced pluripotent stem cell (iPSC) lines. This non-competitive commercial item acquisition was conducted under simplified acquisition procedures without a small business set-aside. The services...
The U.S. National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services (HHS), awarded a $225,000.00 Firm Fixed Price Definitive Contract to Invivosciences, Inc., a small disadvantaged business, for "PHENOTYPIC CARDIOTOXICITY SCREENING WITH HUMAN 3D HEART TISSUES". This award is set aside for total small business participation. Invivosciences provides research and development services in the field of medical science,...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $209,265.00 firm fixed-price purchase order to Fujifilm Cellular Dynamics, Inc., a foreign-owned for-profit manufacturer, for the delivery of iCell and MyCell induced pluripotent stem (iPS) cell-derived differentiated cells. This non-competitive acquisition supports ongoing HEAL-related projects at NCATS' Stem Cell Translation Laboratory, which focus...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $142,843.00 firm-fixed-price purchase order to Hesperos, Inc., a leading company in organ-on-a-chip technology, to provide scientific testing services. The contract is for the target validation and therapeutic evaluation of drug compound TRND00601748-01 in NGLY1 deficient cell-based models, including motoneurons and neuromuscular junction models. This...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Life Technologies Corporation, a manufacturer of scientific instruments, reagents, and consumables. The $24,262.29 contract is for the delivery of primary human hepatocytes, which are a critical reagent used in biomedical research supported by NCATS. This contract is not associated with any set-aside...
This $25,100 firm-fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA) to Lifenet Health, a non-profit organization and manufacturer of regenerative medicine products, to conduct 3D liver spheroid assays for pharmacogenomics-based prediction of drug-induced liver injury (DILI). The award has a period of performance through September 29, 2025 and was not set aside for any particular business type. Lifenet Health is a specialized provider of human tissues and...